| TABLE 2. Pharmacokinetics of dexfenfluramine (DFN) in obese human subjects
given a single oral dose of 30 mg of DFN hydrochloride |
|
DFN
|
|
AUC
(0,t) (mg/L·h)
|
372.7 ± 223.7
|
|
CL
(L/h)
|
43.1
± 21.2
|
|
V
(L/kg)
|
11.2
± 6.2
|
|
t{ewc
MVIMG, MVIMAGE,!onehalf.bmp}ß (h)
|
16.5
± 7.1
|
|
Cmax
(mg/L)
|
20.1
± 6.7
|
|
tmax
(h)
|
3.5 (2.0–5.0)a
|
|
F
(%)
|
0.61
± 0.15
|
|
|
|
DNFN
|
|
AUC
(0,t) (mg/L·h)
|
293.7
± 86.1
|
|
Cmax
(mg/L)
|
7.7
± 2.1
|
|
tmax
(h)
|
6.0 (4.6–8.0)a
|
|
| a Median (range). |
| Results are
for 10 subjects/group (5 males, 5 females) and are given as means ± SD Abbreviations; AUC (0,t)
= area under the plasma concentration-time curve from time zero to the
last time at which the compound was measurable: CL = total clearance:
V = volume of distribution: t{ewc MVIMG, MVIMAGE,!onehalf.bmp}ß = half-life
of terminal phase: Cmax = peak plasma concentration: tmax = time to Cmax:
F = bioavailability. (a) = median (range). (Data from ref. 16) |
| Back to Chapter |